Director Hu Jinglin held a symposium to listen to the opinions and suggestions of some pharmaceutical enterprises

On February 25, Hu Jinglin, director of the State Medical Security Bureau, presided over a symposium to listen to the opinions and suggestions of some pharmaceutical enterprises on medical insurance drug policies Leaders of 14 pharmaceutical enterprises, including Yangzijiang pharmaceutical, Kangenbei group, Beida pharmaceutical, Tianshili pharmaceutical, Qilu pharmaceutical, Junshi biological, Shiyao group, Shenwei pharmaceutical, Zhengda Tianqing, Fosun Pharmaceutical, HISCO pharmaceutical, Pfizer China, Sino US Squibb and Sanofi, attended the meeting Chen Jinfu, deputy director of the State Medical Security Bureau, and the responsible comrades of the office, the Department of medicine management and the Department of price bidding and purchasing attended the meeting The participating enterprises fully affirmed the policies and a series of reform measures formulated by the medical insurance bureau since its establishment, and had a heated discussion on improving the dynamic adjustment mechanism of the medical insurance drug catalog and promoting the centralized purchase and use pilot of drugs organized by the state The participating enterprises proposed to further highlight the policy orientation of encouraging innovation, establish a stable and predictable policy environment, and put forward opinions and suggestions on giving play to the decisive role of the market in resource allocation and better playing the role of the government Hu expressed heartfelt thanks to the participating enterprises This year, we will launch a new round of adjustment of the medical insurance drug catalog, and bring more good drugs for life and emergency into the medical insurance We should actively do a good job in the pilot work of centralized purchase and use of drugs organized by the state In accordance with the requirements of GBF [2019] No 2 document, we should work with relevant departments to urge the pilot areas to implement the results of centralized purchase and strengthen supervision and inspection, so as to ensure the implementation and effectiveness of policies We will fully summarize and evaluate the effectiveness of the pilot project, listen to opinions extensively, and study and gradually expand the scope of the pilot project Hu Jinglin also said that the medical insurance bureau will continue to strengthen communication with pharmaceutical enterprises, improve the pertinence of medical insurance and drug management policies, and strive to let the people enjoy more high-quality and high-price medical services in accordance with the requirements of the executive meeting of the State Council on formulating enterprise related rules and documents to listen to the opinions of enterprises.